Galectins, Glycans, and Mucins as Targets for Novel and Specific Antibody Therapies in Gynecologic Cancer Therapies

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Unknown venue

• Publication date

  2011-09-28

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1159/000328906
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Safety and efficacy of panitumumab following cetuximab: retrospective review of the Memorial Sloan-Kettering experience

  2010cited by this paper
• Bevacizumab for ocular neovascular diseases: a systematic review

  2009cited by this paper
• MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells

  2009cited by this paper
• FDA review of a panitumumab (Vectibix) clinical trial for first-line treatment of metastatic colorectal cancer.

  2009cited by this paper
• Evaluation of a Novel Anti-Mucin 1 (MUC1) Antibody (PankoMab) as a Potential Diagnostic Tool in Human Ductal Breast Cancer; Comparison with Two Established Antibodies

  2009cited by this paper
• Targeted therapy: comprehensive review.

  2009cited by this paper
• Salvage therapy of pretreated advanced breast cancer with bevacizumab and paclitaxel every two weeks: a retrospective case review study

  2009cited by this paper
• Recent Advances Relating to the Clinical Application of Naked Monoclonal Antibodies in Solid Tumors

  2009cited by this paper
• The Human Endometrium Expresses the Glycoprotein Mucin-1 and Shows Positive Correlation for Thomsen-Friedenreich Epitope Expression and Galectin-1 Binding

  2009cited by this paper
• Retrospective chart review of severe infusion reactions with rituximab, cetuximab, and bevacizumab in community oncology practices: assessment of clinical consequences

  2008cited by this paper
• Contribution of membrane mucins to tumor progression through modulation of cellular growth signaling pathways.

  2007cited by this paper
• Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.

  2007cited by this paper
• Binding of galectin-1 (gal-1) to the Thomsen–Friedenreich (TF) antigen on trophoblast cells and inhibition of proliferation of trophoblast tumor cells in vitro by gal-1 or an anti-TF antibody

  2006cited by this paper
• PankoMab: a potent new generation anti-tumour MUC1 antibody

  2006cited by this paper
• Prognostic impact of Thomsen–Friedenreich tumor antigen and disseminated tumor cells in the bone marrow of breast cancer patients

  2006cited by this paper
• What Makes MUC1 a Tumor Antigen?

  2005cited by this paper
• Characterisation of disseminated tumor cells in the bone marrow of breast cancer patients by the Thomsen–Friedenreich tumor antigen

  2005cited by this paper
• MUC1 Oncoprotein Blocks Glycogen Synthase Kinase 3β–Mediated Phosphorylation and Degradation of β-Catenin

  2005cited by this paper
• Binding patterns of DTR-specific antibodies reveal a glycosylation-conditioned tumor-specific epitope of the epithelial mucin (MUC1).

  2004cited by this paper
• Endogenous galactoside-binding lectins: a new class of functional tumor cell surface molecules related to metastasis

  2004cited by this paper
• Tumor-targeted gene delivery via anti-HER2 antibody (trastuzumab, Herceptin) conjugated polyethylenimine.

  2004cited by this paper
• Binding of galectin-1 (gal-1) on trophoblast cells and inhibition of hormone production of trophoblast tumor cells in vitro by gal-1

  2004cited by this paper
• Mucins in cancer: protection and control of the cell surface

  2004cited by this paper
• A novel biological activity for galectin-1: inhibition of leukocyte-endothelial cell interactions in experimental inflammation.

  2003cited by this paper
• Cell signaling through membrane mucins.

  2003cited by this paper
• Expression of the Thomsen-Friedenreich antigen and of its putative carrier protein mucin 1 in the human placenta and in trophoblast cells in vitro

  2002cited by this paper
• Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells.

  2002cited by this paper
• Immunoreactivity of Monoclonal Antibody BW835 Represents a Marker of Progression and Prognosis in Early Gastric Cancer

  2001cited by this paper
• A STAT-responsive Element in the Promoter of the Episialin/MUC1 Gene Is Involved in Its Overexpression in Carcinoma Cells*

  2001cited by this paper
• Immunohistochemical expression of T, Tn and sialyl-Tn antigens and clinical outcome in human breast carcinoma.

  2001cited by this paper
• The c-Src Tyrosine Kinase Regulates Signaling of the Human DF3/MUC1 Carcinoma-associated Antigen with GSK3β and β-Catenin*

  2001cited by this paper
• EMA: a differentiation antigen related to node metastatic capacity of breast carcinomas.

  2001cited by this paper
• The importance of MUC1 cellular localization in patients with breast carcinoma

  2001cited by this paper
• Effects of Thomsen-Friedenreich antigen-specific peptide P-30 on beta-galactoside-mediated homotypic aggregation and adhesion to the endothelium of MDA-MB-435 human breast carcinoma cells.

  2000cited by this paper
• Multiple facets of sialomucin complex/MUC4, a membrane mucin and erbb2 ligand, in tumors and tissues (Y2K update).

  2000cited by this paper
• Thomsen‐Friedenreich antigen presents as a prognostic factor in colorectal carcinoma

  2000cited by this paper
• Aberrant expression of muc1 mucin in ductal hyperplasia and ductal carcinoma In situ of the breast

  1999cited by this paper
• Galectins-1 and -3 and their ligands in tumor biology

  1999cited by this paper
• Membrane Mucins and Breast Cancer.

  1999cited by this paper
• Expression of Thomsen-Friedenreich antigen as a marker of poor prognosis in pulmonary adenocarcinoma.

  1999cited by this paper
• First Trimester Human Endovascular Trophoblast Cells Express Both HLA‐C and HLA‐G

  1999cited by this paper
• MUC1 (episialin) expression in non-small cell lung cancer is independent of EGFR and c-erbB-2 expression and correlates with poor survival in node positive patients.

  1998cited by this paper
• Interaction of Glycogen Synthase Kinase 3β with the DF3/MUC1 Carcinoma-Associated Antigen and β-Catenin

  1998cited by this paper
• Expression of N-linked sialyl Le(x) determinants and O-glycans in the carbohydrate moiety of human amniotic fluid transferrin during pregnancy.

  1998cited by this paper
• Immunohistochemical Characterization of a Panel of 56 Antibodies with Normal Human Small Intestine, Colon, and Breast Tissues

  1997cited by this paper
• The galectin family of mammalian carbohydrate-binding molecules.

  1997cited by this paper
• Summary Report on the ISOBM TD-4 Workshop: Analysis of 56 Monoclonal Antibodies against the MUC1 Mucin

  1997cited by this paper
• Galectin-1 is expressed by thymic epithelial cells in myasthenia gravis

  1996cited by this paper
• Thomsen-Friedenreich-related carbohydrate antigens in normal adult human tissues: a systematic and comparative study

  1996cited by this paper
• Apoptosis of T cells mediated by galectin-1

  1995cited by this paper
• Immunohistochemical and glycohistochemical localization of the beta-galactoside-binding S-type lectin in human placenta.

  1995cited by this paper
• Adhesion and invasion of three human choriocarcinoma cell lines into human endometrium in a three-dimensional organ culture system.

  1994cited by this paper
• Galectins: a family of animal beta-galactoside-binding lectins.

  1994cited by this paper
• Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell interaction.

  1993cited by this paper
• Identification of an autocrine negative growth factor: mouse beta-galactoside-binding protein is a cytostatic factor and cell growth regulator.

  1991cited by this paper
• Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin.

  1990cited by this paper
• Recombinant human β-galactoside binding lectin suppresses clinical and histological signs of experimental autoimmune encephalomyelitis

  1990cited by this paper
• Are pancarcinoma T and Tn differentiation antigens?

  1989cited by this paper
• Increased expression of Thomsen-Friedenreich antigens during tumor progression in breast cancer patients.

  1988cited by this paper
• Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer.

  1986cited by this paper
• Antigen expression by trophoblast populations in the human placenta and their possible immunobiological relevance.

  1985cited by this paper
• Sodium butyrate induction of milk-related antigens in human MCF-7 breast carcinoma cells.

  1984cited by this paper
• Histochemical methods for the demonstration of Thomsen-Friedenreich antigen in cell suspensions and tissue sections. [Klin. Wochenschr. 56, 761--765 (1978)].

  1978cited by this paper
• Blood group MN precursors as human breast carcinoma‐associated antigens and “naturally” occurring human cytotoxins against them

  1976cited by this paper

• No citing papers are available for this paper.